Pharmaceutical company Upsher-Smith Laboratories LLC revealed on Friday the launch of an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products, with combined annual sales of more than USD1.6bn (IQVIA, 12 months ending March 2018).
This partnership collaboration is part of its company-wide effort to grow its generics pipeline as well as expand its strategic relationships within the pharmaceutical industry.
The agreement allows Upsher-Smith to register the products with the US Food and Drug Administration (FDA) as well as market and distribute them under its own label in the US upon US FDA approval.
In conjunction, the partner company will develop and manufacture the products exclusively for Upsher-Smith.
Financial terms related to the deal have not been disclosed by the companies.
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz